日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Reaching for top echelon in R&D of new drugs

By ZHOU WENTING in Shanghai | China Daily | Updated: 2021-11-02 09:22
Share
Share - WeChat
A booth of Boehringer-Ingelheim during the 2020 CIIE in Shanghai. [Photo/CHINA DAILY]

China is expected to enter the world's top echelon in the research and development of new drugs within the next decade as many local biomedical companies have cultivated a strong R&D prowess and are thriving in clinical trials, said industry experts.

Such robust development momentum, which has been on the rise over the past five years, is also a result of deepened collaborations with multinational pharmaceutical giants. The country's ecosystem also encourages vibrant innovations under the Health China 2030 Initiative, they said.

Innovation vitality from home and abroad can be propelled mutually and form positive interaction cycles to provide a steady stream of new drugs, said some multinational biotech companies ahead of the fourth China International Import Expo, which will open this week. Since its launch in 2018, the CIIE has evolved into a platform for the world's leading corporations as well as emerging companies to exhibit the latest innovations and step up collaborations with local partners.

The prosperity and enthusiasm of new drug development in China is not seen elsewhere today, said Wang Bin, general manager of Boehringer Ingelheim Biopharma China.

"The speed of innovative and new therapies applying for clinical trials and approved for the market in China each year is outpacing others and has been showing an impressive straight uptrend for years," said Wang.

"And in the next generation of therapies-gene- and cell-related fields-the gap between China and the leading players is smaller than in traditional drugs, thanks to China's quick acceptance of new things and diligence," he said.

The country's health ecosystem to support innovative therapies is a major booster, Wang said. The number of expensive biomedicines included in the national medical reimbursement plan has been rising each year, which created a virtuous circle between making investments and seeing the hope of strong returns on those investments.

The country has also allowed the Contract Development Manufacturing Organization-or CDMO model-to help research-oriented companies focus on R&D while outsourcing drug development and manufacturing. It also lets outsourced providers commercialize products.

"Such supportive policies plus large market need, including the aging trend, have attracted a large number of talented professionals and experts, ranging from young graduates to veterans in pharmaceutical enterprises overseas, to return and their entrepreneurial projects have begun to produce positive results," Wang said.

China is already in the world's second echelon of new drug R&D based on the quantity of the innovative product pipelines. "The divide between it and the first echelon, the United States, is narrowing," said Chen Kaixian, an academic who specializes in new drug research at the Chinese Academy of Sciences.

Citing data between 2017 and 2020, a McKinsey report showed that the ratio of locally developed innovative drugs approved in China leaped from 2 percent to 37 percent, although multinational businesses also accelerated the speed of introducing innovative therapies in the country.

"It's a golden time for China's biomedical R&D and innovations. We can definitely stand at the forefront of the world's biomedical innovation with capital assistance after accumulations and summarizations," said Niu Xiaofeng, R&D director of Elpiscience, a Shanghai-based clinical-stage biopharmaceutical company focusing on cancer immunotherapy.

Elpiscience was among 340 biomedical enterprises competing in the national finals of biotechnology during the China Innovation and Entrepreneurship Competition in October.

The company's more than 10 innovative molecules in discovery, with focus on innate immunity and tumor microenvironment, competed with an innovative antibody drug treating tumors. The company said the project has entered the process development stage and is expected to launch Phase-I clinical trials in 2023.

The vitality of new drug R&D with a richer pipeline in China is closely related to the business environment increasingly conducive to innovations and there exist mutual promotions between the R&D dedications and results from local and international investments, said executives of enterprises from home and abroad.

Dan Brindle, president of Novartis Group (China), said the company has had a strong flow of new drug approvals and therapies or indications included in the national reimbursement drug list to expand patients' accessibility to drugs over the past years.

"We expect that China will become our second-largest market in the near future," said Brindle. "I have to give credit to the foresight of the Chinese government and policymakers who continue to evolve the ecosystem in support of innovation in life sciences."

Brindle cited the example of Entrestro, a Novatis drug launched in China in 2017 to treat heart failure and approved for the new indication of essential hypertension in June.

"China was the world's second market to have the hypertension indication for this therapy. It demonstrated the tremendous progress being made on the regulatory front in the country," he said.

He said that within five years, the company plans to submit 50 new drug applications in China, and aims to achieve simultaneous submissions in China and elsewhere for more than 90 percent of new drugs by 2024.

During the CIIE, Novartis will display some cutting-edge therapies not yet marketed in China, including a first-in-class small interfering RNA-ribonucleic acid-cholesterol-lowering treatment with only two doses a year.

Following the 2019 investment of an additional 863 million yuan ($135 million) to upgrade a Shanghai-based R&D facility, the Roche Innovation Center Shanghai, Roche announced Roche Accelerator, an operation to help accelerate healthcare innovation in China, in May and will demonstrate it during the fourth CIIE.

"As Roche's first in-house accelerator globally, the project will help accelerate the development of healthcare innovation in China and empower the local medical innovation ecosystem," said Vivian Bian, CEO of Roche Pharmaceuticals China.

Startups in the Shanghai-based accelerator with an investment of nearly 300 million yuan each will have access to Roche's full spectrum of local resources ranging from early research and development to commercialization, and will also be provided with research funding support or subsidies.

The company said that scientists from the Roche Innovation Center Shanghai and Roche Group's global R&D centers will engage with entrepreneurs and share their insights.

Also, the accelerator will join hands with strategic partners, including Zhangjiang Group, to foster a batch of startups that will play a leading role in the global innovation ecosystem.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 久久久久久久 | 天天更新天天久久久更新影院 | 国产精品久久久久久久久久久久 | 欧美黑人疯狂性受xxxxx喷水 | 九色九色九色在线综合888 | 中文字幕亚洲欧美 | 在线免费黄色 | 亚洲精品国产精品乱码不97 | 国产精品一区二区三区四区 | 黑人巨大videosjapan高清 婷婷在线免费观看 | 亚洲亚洲人成综合网络 | 日本久久精品免视看国产成人 | 精品影院| 日韩午夜在线视频 | 欧美视频亚洲视频 | 久草视频播放 | 久久新地址 | 99伊人| 国产露脸精品爆浆视频 | 国产精品久久久久久无遮挡 | 日韩一区二区三区在线 | 四色成人av永久网址 | 成人国产一区二区三区 | 国产精品久久久久久久久久iiiii | 国产精品久久久久久久久免费相片 | 91精品一区二区三区久久久久久 | 日韩中文字幕在线播放 | 九一国产精品 | 免费av大全| 精品亚洲成a人片在线观看 在线看片h站 | 一级片视频免费 | 国产精品a久久久久 | 国产小视频在线观看免费 | 亚洲国产aⅴ成人精品无吗 国内成人自拍视频 | 锵锵锵锵锵锵锵锵锵好湿好大 | 亚洲免费精品视频 | 青草青在线 | 色偷偷精品视频在线播放放 | 午夜视频在线观看免费观看在线观看 | 大开眼界电影完整在线看 | 九九九热在线精品免费全部 |